Helsinki, Finland

Goran Maconi

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nanoform Finland Plc. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Goran Maconi: Innovator in Particle Production

Introduction

Goran Maconi is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of particle production, particularly in the pharmaceutical industry. His innovative work has led to the development of systems and methods that enhance the production of particles, which can be crucial for various applications.

Latest Patents

Goran holds 1 patent for a "System, apparatuses, devices, and methods for producing particles." This patent includes embodiments that focus on producing a population of particles, including those corresponding to active pharmaceutical ingredients. His work in this area showcases his commitment to advancing technology in the pharmaceutical sector.

Career Highlights

Goran is currently employed at Nanoform Finland Plc, a company dedicated to transforming the pharmaceutical industry through innovative particle engineering. His role at Nanoform allows him to apply his expertise in particle production, contributing to the development of cutting-edge solutions for drug formulation.

Collaborations

Throughout his career, Goran has collaborated with talented individuals such as Pia Runeberg-Roos and Daniel Veira Canle. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Goran Maconi's work in particle production exemplifies the impact of innovation in the pharmaceutical industry. His contributions through patents and collaborations highlight his role as a key figure in advancing technology for better healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…